Ultragenyx Pharmaceutical (NASDAQ:RARE) Reaches New 1-Year Low on Analyst Downgrade

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s stock price reached a new 52-week low on Tuesday after The Goldman Sachs Group downgraded the stock from a buy rating to a neutral rating. The Goldman Sachs Group now has a $25.00 price target on the stock, down from their previous price target of $61.00. Ultragenyx Pharmaceutical traded as low as $18.37 and last traded at $19.0540, with a volume of 1005279 shares trading hands. The stock had previously closed at $20.27.

RARE has been the topic of a number of other reports. Wells Fargo & Company dropped their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 30th. JPMorgan Chase & Co. dropped their target price on shares of Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a report on Thursday, March 12th. Canaccord Genuity Group reduced their price objective on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Leerink Partners decreased their target price on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 30th. Finally, Guggenheim lowered their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a report on Monday, January 5th. Fifteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $60.47.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Erik Harris sold 10,539 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $240,289.20. Following the completion of the sale, the executive vice president directly owned 89,515 shares of the company’s stock, valued at approximately $2,040,942. The trade was a 10.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Emil D. Kakkis sold 54,404 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $1,240,411.20. Following the completion of the transaction, the chief executive officer directly owned 658,994 shares in the company, valued at $15,025,063.20. This trade represents a 7.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 104,958 shares of company stock valued at $2,394,858 over the last ninety days. Company insiders own 5.50% of the company’s stock.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: Short-interest reports flagged a “large increase” in March but the published figures are 0 shares / NaN with days-to-cover = 0.0 — this appears to be a data/reporting anomaly and is unlikely to be an immediate market driver.
• Negative Sentiment: Goldman Sachs downgraded Ultragenyx from Buy to Neutral and cut its price target from $61 to $25, citing setrusumab data—this removes a major buy-side endorsement and materially reduces analyst-backed upside, increasing selling pressure. Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data
• Negative Sentiment: Multiple law firms have issued class-action and lead-plaintiff notices covering purchases from Aug 3, 2023–Dec 26, 2025 and are soliciting clients ahead of an April 6, 2026 deadline. The surge of litigation notices increases legal and settlement risk and can depress investor sentiment until the claims are resolved. Representative notices: Rosen Law Firm; Pomerantz LLP; The Gross Law Firm.
  RARE DEADLINE: ROSEN investor counsel notice
  Pomerantz investor alert
  Gross Law Firm shareholder alert

Institutional Trading of Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in RARE. Rockefeller Capital Management L.P. boosted its position in shares of Ultragenyx Pharmaceutical by 611.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 7,716 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 6,632 shares during the last quarter. Flax Pond Capital LLC bought a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at about $1,293,000. Caitong International Asset Management Co. Ltd increased its holdings in Ultragenyx Pharmaceutical by 1,116,754.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 122,854 shares of the biopharmaceutical company’s stock valued at $2,826,000 after purchasing an additional 122,843 shares during the last quarter. Alberta Investment Management Corp acquired a new position in Ultragenyx Pharmaceutical in the fourth quarter valued at about $883,000. Finally, Mercer Global Advisors Inc. ADV boosted its holdings in Ultragenyx Pharmaceutical by 17.1% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,965 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 2,036 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Down 8.7%

The stock has a market cap of $1.79 billion, a P/E ratio of -3.17 and a beta of 0.16. The stock has a fifty day simple moving average of $22.59 and a 200-day simple moving average of $28.29.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The company had revenue of $207.28 million during the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The business’s revenue was up 25.5% compared to the same quarter last year. During the same period last year, the company earned ($1.39) earnings per share. Sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.